Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey

OBJECTIVES: To evaluate outcomes and cost-effectiveness of targeted therapy sequencing for metastatic and recurrent cervical cancer. METHOD: Models were simulated based on phase II and III trials on bevacizumab (bev) from GOG-240, cemiplimab (cemi) from GOG 3016, pembrolizumab (pembro) from KEYNOTE-...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Michael T., Attwood, Kristopher, Smith, Gabriella, Liang, Su-Ying, LaVigne Mager, Katherine, Tewari, Krishnansu S., Coleman, Robert L., Kapp, Daniel S., Chan, John K., Monk, Bradley J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469236/
https://www.ncbi.nlm.nih.gov/pubmed/37646470
http://dx.doi.org/10.1177/10732748231182795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469236/
https://www.ncbi.nlm.nih.gov/pubmed/37646470
http://dx.doi.org/10.1177/10732748231182795

Ejemplares similares